
A long-acting injection designed to prevent HIV is set for approval in England and Wales. The cabotegravir (CAB-LA) treatment, administered every two months, will offer a significant alternative to the daily pills currently used for protection against the virus.
This form of pre-exposure prophylaxis (PrEP) is typically taken by HIV-negative people to reduce their risk of infection.